Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer
Introduction: CDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhib...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/1/52 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588695372300288 |
|---|---|
| author | Ram Patel John Mathews Caroline Hamm Swati Kulkarni Rasna Gupta Tarquin Opperman John Dean Chiong Abdullah Nasser |
| author_facet | Ram Patel John Mathews Caroline Hamm Swati Kulkarni Rasna Gupta Tarquin Opperman John Dean Chiong Abdullah Nasser |
| author_sort | Ram Patel |
| collection | DOAJ |
| description | Introduction: CDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhibitors, but the overall survival (OS) outcomes have varied. This study aimed to evaluate the real-world PFS and OS for palbociclib and ribociclib when combined with AIs in patients with HR+/HER2− advanced breast cancer. Materials and Methods: This was a retrospective chart review of adult patients with HR+/HER2− metastatic breast cancer treated at a single academic center between 1 January 2015 and 1 December 2022. The baseline demographics, clinical characteristics, and treatment details were extracted. A Kaplan–Meier analysis was used to estimate the PFS and OS, and differences between the treatment groups were assessed using the log-rank test. Cox proportional hazards models were constructed to adjust for confounding factors. Results: Seventy-five patients were included in the final analysis. The cohort was predominantly female (98.7%) and postmenopausal (77.3%), with 52.0% having de novo stage IV disease. Palbociclib was prescribed to 74.7% of the patients, and ribociclib to 25.3%. The patients receiving ribociclib were significantly younger (57.6 vs. 67.5 years, <i>p</i> = 0.013) and more likely to be premenopausal (42.1% vs. 5.4%, <i>p</i> < 0.001). The real-world median PFS and OS for palbociclib were 20.3 months (95% CI: 14.8–46) and 37.2 months (95% CI: 20.3–not reached [NR]), respectively. For ribociclib, the median PFS and OS were not reached. The Cox proportional hazards models adjusting for age and menopausal status found no significant differences between ribociclib and palbociclib for the PFS (HR = 0.92, <i>p</i> = 0.86) or OS (HR = 0.95, <i>p</i> = 0.92). Conclusion: In this real-world analysis, palbociclib demonstrated a median PFS consistent with the results from landmark trials, although the observed OS was shorter. The ribociclib-treated patients had a numerically longer PFS and OS compared with those treated with palbociclib, but the differences were not statistically significant. The discontinuation rates were similar between the two groups. |
| format | Article |
| id | doaj-art-5235a457ef924c4784b7c71ea532046b |
| institution | Kabale University |
| issn | 1198-0052 1718-7729 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj-art-5235a457ef924c4784b7c71ea532046b2025-01-24T13:28:30ZengMDPI AGCurrent Oncology1198-00521718-77292025-01-013215210.3390/curroncol32010052Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast CancerRam Patel0John Mathews1Caroline Hamm2Swati Kulkarni3Rasna Gupta4Tarquin Opperman5John Dean Chiong6Abdullah Nasser7Schulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, CanadaDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, CanadaDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, CanadaDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, CanadaDepartment of Medical Oncology, Windsor Regional Hospital, Windsor, ON N8W 1L9, CanadaSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, CanadaSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, CanadaSchulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, CanadaIntroduction: CDK4/6 inhibitors in combination with aromatase inhibitors (AIs) are the standard first-line treatment for hormone receptor-positive (HR+), HER2-negative (HER2−) metastatic breast cancer. Landmark trials have demonstrated a comparable progression-free survival (PFS) across CDK4/6 inhibitors, but the overall survival (OS) outcomes have varied. This study aimed to evaluate the real-world PFS and OS for palbociclib and ribociclib when combined with AIs in patients with HR+/HER2− advanced breast cancer. Materials and Methods: This was a retrospective chart review of adult patients with HR+/HER2− metastatic breast cancer treated at a single academic center between 1 January 2015 and 1 December 2022. The baseline demographics, clinical characteristics, and treatment details were extracted. A Kaplan–Meier analysis was used to estimate the PFS and OS, and differences between the treatment groups were assessed using the log-rank test. Cox proportional hazards models were constructed to adjust for confounding factors. Results: Seventy-five patients were included in the final analysis. The cohort was predominantly female (98.7%) and postmenopausal (77.3%), with 52.0% having de novo stage IV disease. Palbociclib was prescribed to 74.7% of the patients, and ribociclib to 25.3%. The patients receiving ribociclib were significantly younger (57.6 vs. 67.5 years, <i>p</i> = 0.013) and more likely to be premenopausal (42.1% vs. 5.4%, <i>p</i> < 0.001). The real-world median PFS and OS for palbociclib were 20.3 months (95% CI: 14.8–46) and 37.2 months (95% CI: 20.3–not reached [NR]), respectively. For ribociclib, the median PFS and OS were not reached. The Cox proportional hazards models adjusting for age and menopausal status found no significant differences between ribociclib and palbociclib for the PFS (HR = 0.92, <i>p</i> = 0.86) or OS (HR = 0.95, <i>p</i> = 0.92). Conclusion: In this real-world analysis, palbociclib demonstrated a median PFS consistent with the results from landmark trials, although the observed OS was shorter. The ribociclib-treated patients had a numerically longer PFS and OS compared with those treated with palbociclib, but the differences were not statistically significant. The discontinuation rates were similar between the two groups.https://www.mdpi.com/1718-7729/32/1/52cyclin-dependent kinase inhibitorsaromatase inhibitorsmetastatic breast cancersurvival analysisreal-world evidence |
| spellingShingle | Ram Patel John Mathews Caroline Hamm Swati Kulkarni Rasna Gupta Tarquin Opperman John Dean Chiong Abdullah Nasser Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer Current Oncology cyclin-dependent kinase inhibitors aromatase inhibitors metastatic breast cancer survival analysis real-world evidence |
| title | Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer |
| title_full | Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer |
| title_fullStr | Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer |
| title_full_unstemmed | Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer |
| title_short | Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2− Advanced Breast Cancer |
| title_sort | real world experience with cdk4 6 inhibitors in the first line palliative setting for hr her2 advanced breast cancer |
| topic | cyclin-dependent kinase inhibitors aromatase inhibitors metastatic breast cancer survival analysis real-world evidence |
| url | https://www.mdpi.com/1718-7729/32/1/52 |
| work_keys_str_mv | AT rampatel realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT johnmathews realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT carolinehamm realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT swatikulkarni realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT rasnagupta realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT tarquinopperman realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT johndeanchiong realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer AT abdullahnasser realworldexperiencewithcdk46inhibitorsinthefirstlinepalliativesettingforhrher2advancedbreastcancer |